President Donald J. Trump is focusing on revitalizing the American pharmaceutical and biotechnology sectors. This initiative aims to enhance national security and stimulate economic growth for American workers.
Gilead Sciences has announced a significant investment in its U.S. operations, committing $11 billion to increase its domestic spending. This move aligns with President Trump's vision of expanding the industry's presence within the United States.
